Drug-coated balloon treatments reduce the risk of target lesion revascularization in treating femoropopliteal artery disease by 67% when compared to plain balloon angioplasty procedures, according to a new study.
Results from the study were published in the Journal of the American College of Cardiology: Cardiovascular Interventions.
The study aimed to compared the risk of target lesion revascularization and all-cause death at 12 months with the 2 different treatments, with secondary objectives that included identifying factors that could have influenced general findings.
A total of 8 trials which compared DCB and PB procedures for femoropopliteal artery disease were examined in the study.
Risk of death was similar between groups while those treated with DCB showed a marked 12-month TLR risk. Long-term outcomes assessments showed reduced incidences of TLR with DCB and a similar incidence of all-cause death.
“DCB significantly reduces the risk of TLR as compared with PB without any effect on all-cause death. Evidence exists for differential efficacy according to the type of device used. Future trials investigating DCB angioplasty should include potentially more effective comparator therapies,” study authors wrote.
